

Supporting Information

New Small-Molecule Alcohol Synthesis by Breaking the Space

Limitation of “Aromatic Cage” in *Pseudomonas* sp. AK1 BBOX

Zhiqin Xu^a, Yaling Mo^a, Zhengwen Li^a, Shurong Ban^{a*}, Heng song^{b,c*}.

^aSchool of Pharmacy, Shanxi Medical University, Taiyuan, Shanxi Province 030001, China

^bCollege of Chemistry & Molecular Science, Wuhan University, Wuhan, Hubei Province 430072, China

^cWuhan University Shenzhen Research Institute, Shenzhen, Guangdong Province 518000, China

*Email: hengsong@whu.edu.cn; shurongban@sxmu.edu.cn

Contents

SDS-PAGE analysis of WT-psBBOX.....	2
Sequence alignment ¹	3
Homology modelling.....	4
Molecular docking.....	5
Construction of psBBOX mutants.....	6
SDS-PAGE analysis of mutants.....	7
Analysis of psBBOX-188A activity.....	7
kinetic analysis.....	8
Synthesis of γ -BB analogues.....	10
Stereoselective synthesis of two configurations of 4a, 7a, 8a.....	11
NMR spectra.....	12
References.....	28

SDS-PAGE analysis of WT-psBBOX




Figure S1 SDS-PAGE analysis of the WT-psBBOX (45.3 KD).

Sequence alignment¹




Figure S2 Sequence alignment of *Pseudomonas* sp. AK1 BBOX (psBBOX gi|231642) and human BBOX (hbBBOX gi|158261239).

Homology modelling




Figure S3 hBBOX template (PDB: 3O2G) (left) and psBBOX model (right).

Molecular docking




Figure S4 Catalytic center of psBBOX is composed of His-350, His-209, Asp211 and Metal ion.




Figure S5 2D graphic of interaction between γ -BB and amino acid residues.

Construction of psBBOX mutants

Table S1 Primers used in this study

Primers	Sequence
184A-F	5'-CGAAAGCAACGCAGGCGTGTGTTGATGTGCG-3'
184A-R	5'-CAGCACGCCTGCGTTGCTTTCGCGAATAAAGC-3'
188A-F	5'-GGCGTGCTGGCAGATGTGCGCAGCAAAGCGG-3'
188A-R	5'-GCGCACATCTGCCAGCACGCCAAAGTTGCTTTCG-3'
201A-F	5'-GATAGCAACGCGGCAACCGCGTTTAACTGCCGCTG-3'
201A-R	5'-GTTAAACGCGGTTGCCGCGTTGCTATCCGCATCC-3'
184Y-F	5'-GCAACTATGGCGTGCTGTTGATGTGCG-3'
184Y-R	5'-GCACGCCATAGTTGCTTTCGCGAATAAAGC-3'
188Y-F	5'-CGTGCTGTATGATGTGCGCAGCAAAGCGGATG-3'
188Y-R	5'-GCACATCATAACAGCACGCCAAAGTTGCTTTCG-3'
201F-F	5'-CAACGCGTTTACCGCGTTTAACTGCCGCG-3'
201F-R	5'-GCGGTAAACGCGTTGCTATCCGCATCCG-3'
368A-F	5'-GCTGCGCAGTGGATCGCGATGAACTGC-3'
368A-R	5'-CGATCCACTGCGCAGCCTTAAAAATGGC-3'
184W-F	5'-GCAACTGGGGCGTGCTGTTTGTG-3'
184W-R	5'-CGCCCCAGTTGCTTTCGCGAATAAAG-3'
188W-F	5'-GCTGTGGGATGTGCGCAGCAAAGC-3'
188W-R	5'-CATCCACAGCACGCCAAAGTTGC-3'
188G-F	5'-GCTGGGTGATGTGCGCAGCAAAG-3'
188G-R	5'-CATCACCCAGCACGCCAAAGTTGC-3'
188V-F	5'-GCTGGTTGATGTGCGCAGCAAAG-3'
188V-R	5'-CATCAACCAGCACGCCAAAGTTGC-3'

Table S2 Construction of mutants based on PCR methods

For 184A, 188A, 201A:

Reaction mixtures (20 μ L)		PCR conditions
0.6 μ L	template DNA	95°C and 3 min,
1 μ L	forward primer	95°C and 30 s
1 μ L	reverse primer	55°C and 30 s
7.4 μ L	H ₂ O	72°C and 4 min 30 s
10 μ L	Gloria Nova HS 2 \times	72°C and 5 min.

} $\times 30$ cycles

For the other mutants:

Reaction mixtures (20 μ L)		PCR conditions
0.6 μ L	template DNA	95°C and 3 min,
1 μ L	forward primer	95°C and 30 s
1 μ L	reverse primer	52°C and 30 s
7.4 μ L	H ₂ O	72°C and 4 min
10 μ L	Gloria Nova HS 2 \times	72°C and 5 min.

} $\times 30$ cycles

SDS-PAGE analysis of mutants




Figure S6 SDS-PAGE analysis of psBBOX mutants.

Analysis of psBBOX-188A activity




Figure S7 Comparison of conversion of quaternary ammonium analogs 4-6 catalyzed by WT and 188A.

kinetic analysis




Figure S8 Dependence of reaction rates on γ -BB, 4 and 7 concentration for wt-psBBOX.




Figure S9 Dependence of reaction rates on 7 and 8 concentration for 188A mutant.





Figure S10 Ratio of oxygen consumption to product formation.

Synthesis of γ -BB analogues



No.	R	R'
4		
5		
6		
7		
8		

Figure S11 Synthetic routes of quaternary ammonium analogues 4~8.


Procedure a²

Ethyl 4-bromobutyrate (1.2equiv.); tertiary amine (1.0equiv. For (4), N,N-Dimethylethylamine; for(5), N,N-Dimethylisopropylamine; for (6), N,N-Diethylmethanamine; for (7), 1-Methylpyrrolidine; for (8), N-Methylpiperidine.) and acetone (10ml) was added to round-bottom flask, room temperature stirred for 12h. Solvents were evaporated in vacuo. Without purification, it can be directly used in the next reaction.

Procedure b²


3M hydrochloric acid was added until pH1, overnight at room temperature, the product was purified by cationic exchange resin.

Stereoselective synthesis of two configurations of 4a, 7a, 8a.



No.	R	R'
4a-S		
7a-S		
8a-S		

Figure S12 Synthetic routes of 4a-S, 7a-S, 8a-S.





No.	R	R'
4a-R		
7a-R		
8a-R		

Figure S13 Synthetic routes of 4a-R, 7a-R, 8a-R.

Procedure a³: Adding 193mg sodium hydroxide into 3.5ml water, stir to dissolve it, cool down in the ice bath, add 2.5mmol corresponding tertiary amine and 3mmol Ethyl (R)-(+)-4-chloro-3-hydroxybutyrate or Ethyl (S)-4-chloro-3-hydroxybutyrate successively, react in the ice bath for 1h, and temperature rise to room temperature for 12h.

Procedure b³: Adding 3M hydrochloric acid to pH 6, purification using cationic resin.

NMR spectra



4-[isopropyl(dimethyl)ammonio]butanoate; **5**





Figure S16 ¹H NMR spectra of **5**.




Figure S17 ¹³C NMR spectra of **5**.

4-[diethyl(methyl)ammonio]butanoate; **6**





Figure S18 ¹H NMR spectra of **6**.




Figure S19 ¹³C NMR spectra of **6**.





Figure S20 ¹H NMR spectra of **7**.




Figure S21 ¹³C NMR spectra of **7**.





Figure S22 ^1H NMR spectra of 8.




Figure S23 ^{13}C NMR spectra of 8.

4-(ethyltrimethylammonio)-3-hydroxybutanoate; 4a





Figure S24 ¹H NMR spectra of 4a.




Figure S25 ¹³C NMR spectra of 4a.

3-hydroxy-4-(1-methylpyrrolidin-1-ium-1-yl)butanoate; 7a





Figure S26 ¹H NMR spectra of 7a.




Figure S27 ¹³C NMR spectra of 7a.

3-hydroxy-4-(1-methylpiperidin-1-ium-1-yl)butanoate; 8a





Figure S28 ¹H NMR spectra of 8a.




Figure S29 ¹³C NMR spectra of 8a.

(R)-4-(ethylidimethylammonio)-3-hydroxybutanoate; 4a-R





Figure S30 ¹H NMR spectra of 4a-R.




Figure S31 ¹³C NMR spectra of 4a-R.

(S)-4-(ethyldimethylammonio)-3-hydroxybutanoate; 4a-S





Figure S32 ¹H NMR spectra of 4a-S.




Figure S33 ¹³C NMR spectra of 4a-S.

(R)-3-hydroxy-4-(1-methylpyrrolidin-1-ium-1-yl)butanoate; 7a-R





Figure S34 ¹H NMR spectra of 7a-R.




Figure S35 ¹³C NMR spectra of 7a-R.

(S)-3-hydroxy-4-(1-methylpyrrolidin-1-ium-1-yl)butanoate; 7a-S





Figure S36 ¹H NMR spectra of 7a-S.




Figure S37 ¹³C NMR spectra of 7a-S.

(R)-3-hydroxy-4-(1-methylpiperidin-1-ium-1-yl)butanoate; 8a-R





Figure S38 ¹H NMR spectra of 8a-R.




Figure S39 ¹³C NMR spectra of 8a-R.

(S)-3-hydroxy-4-(1-methylpiperidin-1-ium-1-yl)butanoate; 8a-S





Figure S40 ¹H NMR spectra of 8a-S.




Figure S41 ¹³C NMR spectra of 8a-S.




Figure S42 ^1H NMR monitoring of the 2 hydroxylation by psBBOX.




Figure S43 ^1H NMR monitoring of the 2 hydroxylation by psBBOX.




Figure S44 The inhibitory effect of (5), (6), (8) on the transformation of original substrate (1).

References

1. Robert, X.; Gouet, P., Deciphering key features in protein structures with the new ENDscript server. *Nucleic acids research* **2014**, *42* (W1), W320-W324.
2. Ryzik, A. M.; Chowdhury, R.; Kochan, G. T.; Williams, S. T.; McDonough, M. A.; Kawamura, A.; Schofield, C. J., Modulating carnitine levels by targeting its biosynthesis – selective inhibition of γ -butyrobetaine hydroxylase. *Chemical Science* **2014**, *5* (5), 1765–1771.
3. 吴静; 刘九知; 白洁; 孙德夫 一种左卡尼汀化合物的制备方法. CN104030934B, 2016-06-15.